基于[18F]RCCB6的透明细胞肾细胞癌免疫PET/CT显像:首次人体研究
本研究开发了四种靶向CD70的单域抗体并用18F标记,在透明细胞肾细胞癌PDX模型中评估显像特性,并在注册前瞻性临床试验(NCT06148220)中纳入6例病理确诊肾细胞癌患者行[18F]RCCB6免疫PET/CT检查。临床转化结果显示[18F]RCCB6有潜力识别透明细胞肾细胞癌患者的复发和/或转移。
要点
- 成功制备四种靶向CD70的单域抗体,经AlF-RESCA法进行18F标记。
- 在PDX模型中[18F]RCCB6肿瘤摄取较高、骨累积较低,诊断潜力优于[18F]RCCB3。
- 首次人体研究中[18F]RCCB6免疫PET/CT在多名患者中显示透明细胞肾细胞癌转移灶。
核心结论
- 成功开发一系列靶向CD70的免疫PET/CT显像示踪剂,其中[18F]RCCB6在临床前研究中清晰且特异地识别接种的透明细胞肾细胞癌。
- [18F]RCCB6的临床转化提示其有潜力识别透明细胞肾细胞癌患者的复发和/或转移。
研究设计与样本
- 临床前研究制备四种靶向CD70的单域抗体并用AlF-RESCA法进行18F标记,在皮下透明细胞肾细胞癌PDX模型中评估显像特性。
- 注册前瞻性临床试验(NCT06148220)纳入6例病理确诊肾细胞癌患者,行[18F]RCCB6免疫PET/CT检查。
主要发现
- 工程化制备四种单域抗体(His标签RCCB3和RCCB6、无His标签RB3和RB6),特异性靶向重组人CD70且不与鼠CD70交叉反应。
- 在皮下透明细胞肾细胞癌PDX模型中,[18F]RCCB3和[18F]RCCB6免疫PET/CT显示高肿瘤/本底比值,后者肿瘤摄取更高、骨累积更低,诊断潜力更好。
- 经序列优化开发的[18F]RB6肾脏累积显著低于[18F]RCCB6。
- 在初步转化研究中,[18F]RCCB6免疫PET/CT在多名患者中显示透明细胞肾细胞癌转移灶,并在1例透明细胞肾细胞癌患者中显示优于18F-FDG PET/CT的显像对比度和诊断价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The cluster of differentiation (CD70) is a potential biomarker of clear cell renal cell carcinoma (ccRCC). This study aims to develop CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers and explore the diagnostic value in preclinical studies and the potential value in detecting metastases in ccRCC patients. METHODS: Four novel CD70-specific single-domain antibodies (sdAbs) were produced and labelled with 18F by the aluminium fluoride restrained complexing agent (AlF-RESCA) method to develop radiotracers. The visualisation properties of the tracers were evaluated in a subcutaneous ccRCC patient-derived xenograft (PDX) model. In a registered prospective clinical trial (NCT06148220), six patients with pathologically confirmed RCC were included and underwent immunoPET/CT examination exploiting one of the developed tracers (i.e., [18F]RCCB6). RESULTS: We engineered four sdAbs (His-tagged RCCB3 and RCCB6, His-tag-free RB3 and RB6) specifically targeting recombinant human CD70 without cross-reactivity to murine CD70. ImmunoPET/CT imaging with [18F]RCCB3 and [18F]RCCB6 demonstrated a high tumour-to-background ratio in a subcutaneous ccRCC PDX model, with the latter showing better diagnostic potential supported by higher tumour uptake and lower bone accumulation. In comparison, [18F]RB6, developed by sequence optimisation, has significantly lower kidney accumulation than that of [18F]RCCB6. In a pilot translational study, [18F]RCCB6 immunoPET/CT displayed ccRCC metastases in multiple patients and demonstrated improved imaging contrast and diagnostic value than 18F-FDG PET/CT in a patient with ccRCC. CONCLUSION: The work successfully developed a series of CD70-targeted immunoPET/CT imaging tracers. Of them, [18F]RCCB6 clearly and specifically identified inoculated ccRCCs in preclinical studies. Clinical translation of [18F]RCCB6 suggests potential for identifying recurrence and/or metastasis in ccRCC patients.
引用
- Wu Q, Wu Y, Zhang Y, et al. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38480552. doi:10.1007/s00259-024-06672-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。